13F Insight
DOSSIER · 13F-HR · Q2 2026

CAXTON CORP

$4M in tracked AUM across 11 positions as of Q2 2026.

CC
CIK 0001388551 · last filed Jun 30, 2026
Total AUM
$4M
as of Q2 2026
Holdings
11
—
positions
Whale Score
59
59
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026

1. Portfolio Overview

Caxton Corp's latest 13F filing for the period ending September 30, 2025, reveals a highly concentrated portfolio that has undergone significant expansion and strategic pivoting. The total portfolio value surged by 122.8%, growing from $9.85 million in the previous quarter to $21.95 million. This substantial increase in assets under management (AUM) was driven primarily by a massive capital injection into a single equity position rather than broad-based market appr...

The portfolio currently holds 8 distinct positions, indicating a high-conviction strategy with minimal diversification. The allocation is extremely top-heavy, with the top two holdings—Rezolute Inc and the SPDR Gold Trust—accounting for approximately 96.9% of the total portfolio value. This structure suggests a "barbell" approach, combining a high-beta, high-conviction healthcare stock with a traditional safe-haven asset (gold), while maintaining smaller, speculative positions in the biotech sector.

2. Key Holdings

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
SPCX
SPACE EXPLORATION TECHN CORP
$445K3K24.0%02
BRK/B
BERKSHIRE HATHAWAY INC DEL
$377K75420.3%03
GOOGL
ALPHABET INC
$247K69113.3%04
VOO
VANGUARD INDEX FDS
$233K33912.6%05
BX
BLACKSTONE INC
$188K2K10.2%06
KYTX
KYVERNA THERAPEUTICS INC
$110K12K5.9%07
LXEO
LEXEO THERAPEUTICS INC
$79K17K4.3%08
XFOR
X4 PHARMACEUTICALS INC
$73K16K3.9%09
IKT
INHIBIKASE THERAPEUTICS INC
$58K28K3.1%10
ALXO
ALX ONCOLOGY HLDGS INC
$43K21K2.3%

Filing history

2026Q2Jun 30
$2M▼ 53.9%
10 positionsView →2026Q1Mar 31
$4M▼ 6.0%
7 positionsView →2025Q4Dec 31
$4M▼ 80.5%
11 positionsView →2025Q3Sep 30
$22M▲ 122.8%
8 positionsView →2025Q2Jun 30
$10M▲ 112.7%
11 positionsLocked2025Q1Mar 31
$5M▼ 72.2%
8 positionsLocked2024Q4Dec 31
$17M▼ 31.1%
15 positionsLocked2024Q3Sep 30
$24M▲ 22.5%
12 positionsLocked2024Q2Jun 30
$20M▲ 12.4%
12 positionsLocked2024Q1Mar 31
$18M▼ 5.3%
11 positionsLocked2023Q4Dec 31
$19M▼ 29.6%
12 positionsLocked2023Q3Sep 30
$26M▼ 24.0%
9 positionsLocked
Showing 12 of 53